Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
3
50%
Ph not_applicable
2
33%
Ph phase_1
1
17%

Phase Distribution

1

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 4Post-market surveillance
3(50.0%)
N/ANon-phased studies
2(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(2)
Terminated(1)
Other(1)

Detailed Status

Recruiting2
Completed2
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (16.7%)
Phase 43 (50.0%)
N/A2 (33.3%)

Trials by Status

recruiting233%
unknown117%
withdrawn117%
completed233%

Recent Activity

2 active trials
Showing 5 of 6
completedphase_4

Medication Facilitated Ureteral Access Sheath Deployment During Ureteroscopy: The Impact of One Week of Preoperative Tamsulosin

NCT07847866
recruitingnot_applicable

Tamsulosin Monotherapy Versus Combination Therapy With Tadalafil (2.5 mg vs 5 mg) in Managing Male LUTS Secondary to BPH

NCT07722884
recruitingphase_4

Tamsulosin Dose Escalation or Silodosin Switch Before Trial Without Catheter in BPH-Related Acute Urinary Retention

NCT07650968
completedphase_4

Efficacy and Safety of Tadalafil, Tamsulosin, and Their Combinations in Treating Lower Urinary Tract Symptoms in BPH Patients with Prostate Volumes ≤ 40 Ml: a Prospective Comparative Study

NCT06809205
unknownnot_applicable

Treatment of BPH With CO2 Serenoa +PEA as Monotherapy or in Combination With Tamsulosin: ProSeRePEA Trial

NCT06181175
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07847866Phase 4

Medication Facilitated Ureteral Access Sheath Deployment During Ureteroscopy: The Impact of One Week of Preoperative Tamsulosin

Completed
NCT07722884Not Applicable

Tamsulosin Monotherapy Versus Combination Therapy With Tadalafil (2.5 mg vs 5 mg) in Managing Male LUTS Secondary to BPH

Recruiting
NCT07650968Phase 4

Tamsulosin Dose Escalation or Silodosin Switch Before Trial Without Catheter in BPH-Related Acute Urinary Retention

Recruiting
NCT06809205Phase 4

Efficacy and Safety of Tadalafil, Tamsulosin, and Their Combinations in Treating Lower Urinary Tract Symptoms in BPH Patients with Prostate Volumes ≤ 40 Ml: a Prospective Comparative Study

Completed
NCT06181175Not Applicable

Treatment of BPH With CO2 Serenoa +PEA as Monotherapy or in Combination With Tamsulosin: ProSeRePEA Trial

Unknown
NCT03384524Phase 1

Evaluation of Bromocriptine, Metoprolol and Tamsulosin in Eyes With Non-Central DME

Withdrawn

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6